Author

A. Zaliani

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Scientific Communication & Education· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:statistical model· 2 Research Focus:benchmarking· 1 Research Focus:database / resource· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Research Focus:software / tool· 1 Assay:structural biology· 1 Organism:virus· 1

Frequent Co-Authors

P. Gribbon· 2 shared A. Hanke· 1 shared A. R. Beccari· 1 shared B. P. Joseph· 1 shared C. Bergh· 1 shared C. Manelfi· 1 shared C. Talarico· 1 shared D. B. Kokh· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersScientific Communication & Education

P. Gribbon

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmaceutical patent landscaping: A novel approach to understand patents from the drug discovery perspective

Y. Gadiya, P. Gribbon, M. Hofmann-Apititus, A. Zaliani

This paper uses patent data to analyze trends and potential drug targets in rare diseases and Alzheimer's disease, identifying repurposed drugs and new therapeutic approaches.

Artificial Intelligence in the Life Sciences · Dec 1, 2023Peer-reviewedScientific Communication & Education

A blueprint for high affinity SARS-CoV-2 Mpro inhibitors from activity-based compound library screening guided by analysis of protein dynamics

J. Gossen, S. Albani, A. Hanke, B. P. Joseph, C. Bergh, M. Kuzikov, E. Costanza, C. Manelfi, P. Storici, P. Gribbon, A. R. Beccari, C. Talarico, F. Spyrakis, E. Lindahl, A. Zaliani, , G. Rossetti

The paper identifies a blueprint for high affinity SARS-CoV-2 Mpro inhibitors by analyzing protein dynamics and redefining druggability through virtual screening and pharmacophore modeling.

bioRxiv · Dec 14, 2020Biophysics